MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2

Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding mo...

Full description

Saved in:
Bibliographic Details
Main Authors HOFFMANN, Dietmar, ZHU, Yunxiang, BRONDYK, William, ZHAO, Hongmei, SEVIGNY, Leila, WEI, Ronnie, DEVAUD, Catherine, LANGE, Christian, MAGNAY, Tristan, BEIL, Christian, PRADES, Catherine, RAO, Ercole, CHEN, Yangde, CHENG, Seng, CONNORS, Timothy, MAGNAY, Maureen
Format Patent
LanguageEnglish
French
Published 20.06.2019
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies. La présente invention concerne des molécules de liaison multispécifiques (par exemple, bispécifiques) comprenant un premier domaine de liaison qui se lie à une partie extracellulaire du dystroglycane et un second domaine de liaison qui se lie à la laminine-2. La présente invention concerne en outre des procédés pour la fabrication de telles molécules de liaison et des utilisations de telles molécules de liaison pour le traitement et/ou la prévention d'alpha-dystroglycanopathies.
Bibliography:Application Number: WO2018US00056